KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2025)

Historic Change in Cash for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $133.3 million.

  • Recursion Pharmaceuticals' Change in Cash rose 38408.85% to $133.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.3 million, marking a year-over-year increase of 49888.67%. This contributed to the annual value of $201.6 million for FY2024, which is 22784.76% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Change in Cash of $133.3 million as of Q3 2025, which was up 38408.85% from $24.7 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Cash registered a high of $423.8 million during Q2 2021, and its lowest value of -$238.0 million during Q3 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Change in Cash averaged around $21.1 million, with its median value being -$19.6 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Change in Cash plummeted by 261500.0% in 2023 and then skyrocketed by 386379.8% in 2024.
  • Recursion Pharmaceuticals' Change in Cash (Quarter) stood at -$109.6 million in 2021, then soared by 185.97% to $94.2 million in 2022, then crashed by 95.52% to $4.2 million in 2023, then soared by 3863.8% to $167.2 million in 2024, then decreased by 20.27% to $133.3 million in 2025.
  • Its Change in Cash was $133.3 million in Q3 2025, compared to $24.7 million in Q2 2025 and -$93.9 million in Q1 2025.